Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$6.65
+1.2%
$4.61
$1.92
$11.60
$346.92M2.41612,631 shs521,346 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
+1.22%-24.77%+73.63%+38.54%+128.52%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
3.3197 of 5 stars
3.01.00.04.60.63.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
2.00
Hold$9.0035.34% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/A$2.86 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)

Latest 1SN, HE1, CUSN, and KOD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$1.01N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$0.89-$1.09-$0.20-$1.09N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/A
4.62
4.62

Institutional Ownership

CompanyInstitutional Ownership
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
89.06%

Insider Ownership

CompanyInsider Ownership
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
45.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
9052.76 million28.55 millionOptionable

Recent News About These Companies

Part 1: Johnson recounts PTSD treatment after May breakdown
Enduring the heat of California
Penny Stocks To Watch In July 2025
Alaska Aerospace, UAF to partner on new space ventures

New MarketBeat Followers Over Time

Media Sentiment Over Time

Kodiak Sciences stock logo

Kodiak Sciences NASDAQ:KOD

$6.65 +0.08 (+1.22%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$6.78 +0.13 (+1.95%)
As of 08/1/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.